Royal Brompton Hospital , Sydney Street, London SW3 6NP , UK
Expert Opin Investig Drugs. 2014 Mar;23(3):411-5. doi: 10.1517/13543784.2014.873785. Epub 2014 Feb 3.
During 2012, a number of respiratory drug projects and individual agents were discontinued, for a variety of reasons, including toxicity, lack of efficacy, commercial re-evaluation and change in corporate focus. These included three antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2), which had been evaluated in allergic respiratory disease and (in one case) chronic obstructive pulmonary disease (COPD), and other agents intended for the treatment of asthma, COPD, pulmonary hypertension and lung fibrosis. These have been reviewed against the background of a general reduction in respiratory research by the pharmaceutical industry.
2012 年，由于各种原因，包括毒性、疗效不佳、商业重新评估和公司重点变化，许多呼吸药物项目和个别药物被停止。其中包括三种趋化因子受体同源物分子表达在 Th2 细胞上的拮抗剂（CRTh2），它们曾在过敏性呼吸道疾病和（在一种情况下）慢性阻塞性肺疾病（COPD）中进行过评估，以及其他用于治疗哮喘、COPD、肺动脉高压和肺纤维化的药物。这些药物是在制药行业对呼吸研究的普遍减少的背景下进行审查的。
